Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
MRNA's Cash to Debt is ranked higher than
91% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. MRNA: No Debt )
MRNA' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: -51.97
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -156.56
MRNA's Operating margin (%) is ranked higher than
68% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. MRNA: -156.56 )
MRNA' s 10-Year Operating margin (%) Range
Min: -2259.18   Max: -2.56
Current: -156.56

-2259.18
-2.56
Net-margin (%) -791.33
MRNA's Net-margin (%) is ranked higher than
58% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. MRNA: -791.33 )
MRNA' s 10-Year Net-margin (%) Range
Min: -2269.84   Max: 2.56
Current: -791.33

-2269.84
2.56
ROA (%) -147.37
MRNA's ROA (%) is ranked higher than
52% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. MRNA: -147.37 )
MRNA' s 10-Year ROA (%) Range
Min: -158.44   Max: 1.06
Current: -147.37

-158.44
1.06
Revenue Growth (3Y)(%) -55.90
MRNA's Revenue Growth (3Y)(%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. MRNA: -55.90 )
MRNA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -73   Max: 72
Current: -55.9

-73
72
EBITDA Growth (3Y)(%) -81.80
MRNA's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. MRNA: -81.80 )
MRNA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 121.7
Current: -81.8

0
121.7
EPS Growth (3Y)(%) -82.10
MRNA's EPS Growth (3Y)(%) is ranked higher than
51% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. MRNA: -82.10 )
MRNA' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.1   Max: 101
Current: -82.1

-82.1
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.80
MRNA's P/S is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. MRNA: 10.80 )
MRNA' s 10-Year P/S Range
Min: 0.5   Max: 134.19
Current: 10.8

0.5
134.19
EV-to-EBIT -4.79
MRNA's EV-to-EBIT is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MRNA: -4.79 )
MRNA' s 10-Year EV-to-EBIT Range
Min: -60.9   Max: -0.1
Current: -4.79

-60.9
-0.1
Current Ratio 1.43
MRNA's Current Ratio is ranked higher than
55% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MRNA: 1.43 )
MRNA' s 10-Year Current Ratio Range
Min: 0.03   Max: 21.21
Current: 1.43

0.03
21.21
Quick Ratio 1.43
MRNA's Quick Ratio is ranked higher than
58% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. MRNA: 1.43 )
MRNA' s 10-Year Quick Ratio Range
Min: 0.03   Max: 21.07
Current: 1.43

0.03
21.07

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.86
MRNA's Price/Median PS Value is ranked higher than
75% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. MRNA: 1.86 )
MRNA' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 22.51
Current: 1.86

0.12
22.51
Earnings Yield (Greenblatt) -20.90
MRNA's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. MRNA: -20.90 )
MRNA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -20.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based T Dec 18 2014 
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2- Dec 09 2014 
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-i Nov 20 2014 
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014 
x pie = y Jul 01 2011 
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 
MDRNA Inc. Reports Operating Results (10-Q) Jul 30 2009 
MDRNA Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based... Dec 18 2014
Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its... Dec 09 2014
MARINA BIOTECH, INC. Financials Nov 22 2014
Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its... Nov 20 2014
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance Nov 18 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 17 2014
Marina Biotech Announces Third Quarter 2014 Financial Results Nov 17 2014
10-Q for Marina Biotech, Inc. Nov 16 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2014
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Sep 19 2014
Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors Sep 16 2014
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual... Sep 11 2014
Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences Sep 03 2014
Marina Biotech Regains Compliance With Exchange Act Reporting Obligations Aug 20 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 19 2014
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Aug 05 2014
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Jul 22 2014
Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic... Jun 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK